MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations
Elizabeth D Auckley, Stephanie Yohay, Grace Ying, Aniko Szabo, Jacquelyn Wittmann, Justin Grahl, Mohammed Aldakkak, Samih Z Thalji, Thomas McFall, Razelle Kurzrock, Ben George, Mandana Kamgar · 2026
Read MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations by Elizabeth D Auckley, Stephanie Yohay, Grace Ying, Aniko Szabo, Jacquelyn Wittmann, Justin Grahl, Mohammed Aldakkak, Samih Z Thalji, Thomas McFall, Razelle Kurzrock, Ben George, Mandana Kamgar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13592677.txt.
Description
Elizabeth Auckley and co-authors reviewed this 2026 attempt to treat pancreatic cancer by matching drugs to its KRAS mutations. This cancer is famously lethal, and most tumors carry a KRAS fault that fires a growth pathway. Blocking the MEK link in that pathway, combined with other targeted drugs, is one strategy. The team gathered 29 patients with spread disease treated at one center from 2022 to 2024.
The three KRAS variants split almost evenly. Most patients got the therapy as a third or later line. Survival after starting ran longest, at about eight months, for one variant, though the gaps were not significant. About a fifth stopped a drug over side effects. The authors call the control modest for one variant and minimal for the others in late-line use.
Catalog record
| CREATOR | Elizabeth D Auckley, Stephanie Yohay, Grace Ying, Aniko Szabo, Jacquelyn Wittmann, Justin Grahl, Mohammed Aldakkak, Samih Z Thalji, Thomas McFall, Razelle Kurzrock, Ben George, Mandana Kamgar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |